After 18 years of setbacks and disappointments, Marinus Pharmaceuticals has submitted to the US Food and Drug Administration its candidate ganaxolone to treat a rare genetic form of epilepsy.
Established back in 2003, the company has just one drug candidate, GABA-A modulator ganaxolone, and over the years has seen...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
